Mark Grammer ROCHESTER MEDICAL CORP. ROCM-Q COMMENT Jun 06, 2007

Prefers this over Novartis

Mark Grammer

Unknown

Unlock Rating

$14.850

Stock price when the opinion was issued

biotechnology pharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

Most Recent Experts

Andrew Pyle

The Pyle Group, Scotia Wealth Mgt.

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Martin Cobb, ASIP

Lorne Steinberg Wealth Management

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Derek Warren

Lincluden Investment Mgmnt

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Mark Grammer ROCHESTER MEDICAL CORP. ROCM-Q COMMENT Jun 06, 2007

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals